Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-09 · 1879 (5) · 189171
DOI: 10.1016/j.bbcan.2024.189171 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-09. Verfasst von Peng Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266100, China. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 190 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Osteosarcoma, a rare primary bone cancer, presents diverse molecular aberrations that underscore its complexity. Despite the persistent endeavors by researchers, the limited amelioration in the five-year survival rate indicates that current therapeutic strategies prove inadequate in addressing the clinical necessities. Advancements in molecular profiling have facilitated an enhanced comprehension of the biology of osteosarcoma, offering a promising outlook for treatment. There is an urgent need to develop innovative approaches to address the complex challenges of osteosarcoma, ultimately contributing to enhanced patient outcomes. This review explores the nexus between osteosarcoma and cancer predisposition syndromes, intricacies in its somatic genome, and clinically actionable alterations. This review covers treatment strategies, including surgery, chemotherapy, immune checkpoint inhibitors (ICIs), and tyrosine kinase inhibitors (TKIs). Innovative treatment modalities targeting diverse pathways, including multi-target tyrosine kinases, cell cycle, PI3K/mTOR pathway, and DNA damage repair (DDR), offer promising interventions. This review also covers promising avenues, including antibody-drug conjugates (ADCs) and immunotherapy strategies, such as cytokines, adoptive cellular therapy (ACT), ICIs, and cancer vaccines. This comprehensive exploration contributes to a holistic understanding, offering guidance for clinical applications to advance the management of osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266100, China.
- Department of Orthopedic Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266100, China. Electronic address: bonetumoryb@qdu.edu.cn.
- Department of Pharmacy, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266100, China. Electronic address: cristinaxinyiwang@qdu.edu.cn.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yan, P., Wang, J., Yue, B., & Wang, X. (2024). Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(5), 189171. https://doi.org/10.1016/j.bbcan.2024.189171
Vancouver
Yan P, Wang J, Yue B, Wang X. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(5):189171. doi:10.1016/j.bbcan.2024.189171
BibTeX
@article{Yan2024,
author = {Yan, Peng and Wang, Jie and Yue, Bin and Wang, Xinyi},
title = {Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {5},
pages = {189171},
doi = {10.1016/j.bbcan.2024.189171}
}
EUVIMED